Regen BioPharma Files 8-K on Financials
Ticker: RGBPP · Form: 8-K · Filed: Nov 29, 2024 · CIK: 1589150
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Regen BioPharma dropped its latest financial report, check the 8-K for the numbers.
AI Summary
Regen BioPharma Inc. filed an 8-K on November 29, 2024, reporting on its financial condition and results of operations as of September 30, 2024. The filing details the company's financial statements and exhibits, providing an update on its operational and financial status for the period ending on that date.
Why It Matters
This filing provides investors with the latest official financial data for Regen BioPharma, crucial for understanding the company's performance and making informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant changes.
Key Players & Entities
- Regen BioPharma Inc. (company) — Filer of the 8-K report
- November 29, 2024 (date) — Filing date of the 8-K
- September 30, 2024 (date) — Period end date for financial reporting
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regen BioPharma Inc.'s Results of Operations and Financial Condition, along with its Financial Statements and Exhibits as of September 30, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on November 29, 2024.
What is the fiscal year end for Regen BioPharma Inc.?
The fiscal year end for Regen BioPharma Inc. is September 30.
What is the principal executive office address for Regen BioPharma Inc.?
The principal executive office address for Regen BioPharma Inc. is 4700 Spring Street, St 304, La Mesa, California 91942.
What is the SIC code for Regen BioPharma Inc.?
The Standard Industrial Classification (SIC) code for Regen BioPharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 409 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-11-29 06:05:44
Filing Documents
- form8-k.htm (8-K) — 32KB
- ex99-1.htm (EX-99.1) — 1008KB
- 0001493152-24-048090.txt ( ) — 4618KB
- rgbp-20240930.xsd (EX-101.SCH) — 35KB
- rgbp-20240930_cal.xml (EX-101.CAL) — 43KB
- rgbp-20240930_def.xml (EX-101.DEF) — 179KB
- rgbp-20240930_lab.xml (EX-101.LAB) — 270KB
- rgbp-20240930_pre.xml (EX-101.PRE) — 231KB
- form8-k_htm.xml (XML) — 569KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 REGEN BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Commission File No. 333-191725 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) (619) 722 5505 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition On October 28, 2024 and subsequently on November 21, 2024 Regen Biopharma, Inc.'s unaudited consolidated financial statements for the Fiscal Year ended September 30, 2024 were included within a Form 1-A, as amended, filed with the United States Securities and Exchange Commission. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. The following exhibits are filed herewith: Exhibit 99.1 Unaudited Financial Statements for the Fiscal Year Ended September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGEN BIOPHARMA, INC. Dated: November 29, 2024 By: /s/ David Koos